Literature DB >> 12821315

Overexpression, purification, and structural analysis of the hydrophobic E5 protein from human papillomavirus type 16.

Dan-Hui Yang1, Alan G Wildeman, Frances J Sharom.   

Abstract

The E5 proteins of human papillomavirus (HPV) are highly hydrophobic transmembrane proteins that display weak transforming activity. The HPV E5 proteins are localized largely to intracellular membranes, such as the Golgi apparatus and endoplasmic reticulum, but also appear in the plasma membrane. Infection with HPV16 is the cause of over 90% of human cervical cancers. HPV E5 is known to interact with growth factor receptors and gap junction proteins and is believed to play a role during the initiation of neoplasia. The structure of HPV E5 and the mechanism of its interactions with growth factor receptors remain largely unknown. In the present studies, the E5 protein of HPV16 was cloned into the pBAD/TOPO vector fused to an N-terminal thioredoxin leader and a C-terminal His-tag, and expressed in Escherichia coli. The identity of the protein was confirmed by immunoblotting using antibodies against a V5-epitope tag engineered into the protein. Due to formation of high molecular mass superaggregates of the protein, two chromatography steps were employed for its purification: (1) gel filtration chromatography to separate the superaggregated protein from other soluble proteins and (2) Ni-chelate affinity chromatography in the presence of detergent. The superaggregates of the E5-fusion protein were broken down to monomers and various oligomers by sonication in the presence of 0.2% SDS. The purified E5-fusion protein was then reconstituted into lipid vesicles and initial structural analysis of the protein was performed using circular dichroism spectroscopy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12821315     DOI: 10.1016/s1046-5928(03)00049-4

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  10 in total

1.  Membrane orientation of the human papillomavirus type 16 E5 oncoprotein.

Authors:  Ewa Krawczyk; Frank A Suprynowicz; Sawali R Sudarshan; Richard Schlegel
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

2.  HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy.

Authors:  Francesca Paolini; Gianfranca Curzio; Marcelo Nazario Cordeiro; Silvia Massa; Luciano Mariani; Fulvia Pimpinelli; Antonio Carlos de Freitas; Rosella Franconi; Aldo Venuti
Journal:  Hum Vaccin Immunother       Date:  2016-12-08       Impact factor: 3.452

Review 3.  Human papillomavirus type 16 E5 protein as a therapeutic target.

Authors:  Sang-Woo Kim; Joo-Sung Yang
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

Review 4.  The E5 proteins.

Authors:  Daniel DiMaio; Lisa M Petti
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

5.  High-risk human papillomavirus E5 oncoprotein displays channel-forming activity sensitive to small-molecule inhibitors.

Authors:  Laura F Wetherill; Kristopher K Holmes; Mark Verow; Marietta Müller; Gareth Howell; Mark Harris; Colin Fishwick; Nicola Stonehouse; Richard Foster; G Eric Blair; Stephen Griffin; Andrew Macdonald
Journal:  J Virol       Date:  2012-02-22       Impact factor: 5.103

Review 6.  Papillomavirus E5: the smallest oncoprotein with many functions.

Authors:  Aldo Venuti; Francesca Paolini; Lubna Nasir; Annunziata Corteggio; Sante Roperto; Maria S Campo; Giuseppe Borzacchiello
Journal:  Mol Cancer       Date:  2011-11-11       Impact factor: 27.401

Review 7.  Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins.

Authors:  Daria A Haręża; Jacek R Wilczyński; Edyta Paradowska
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

8.  The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells.

Authors:  Myriam Gruener; Ignacio G Bravo; Frank Momburg; Angel Alonso; Pascal Tomakidi
Journal:  Virol J       Date:  2007-10-30       Impact factor: 4.099

9.  Anti-tumor effects of genetic vaccines against HPV major oncogenes.

Authors:  Marcelo Nazário Cordeiro; Francesca Paolini; Silvia Massa; Gianfranca Curzio; Elena Illiano; Anna Jéssica Duarte Silva; Rosella Franconi; Massimiliano Bissa; Carlo De Giuli Morghen; Antonio Carlos de Freitas; Aldo Venuti
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 10.  The Not-So-Good, the Bad and the Ugly: HPV E5, E6 and E7 Oncoproteins in the Orchestration of Carcinogenesis.

Authors:  Om Basukala; Lawrence Banks
Journal:  Viruses       Date:  2021-09-22       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.